Dracocephalum heterophyllum Benth flavonoid (DHBF) is a Tibetan and Uighur traditional medicine used to treat various disorders such as hypertension, lung heat, cough, and bronchitis; it has good antioxidant activity. Previous studies have shown that DHBF can reduce blood pressure in renovascular hypertensive rats, improve left ventricular systolic and diastolic function, and improve myocardial contractility. Therefore, we aimed to study the effect of DHBF on cardiomyocyte hypertrophy in cultured cells.
Background
In developed countries, 1-2% of adults suffer from heart failure, and the proportion can be >10% in people older than the age of 70 [1] . Brouwers et al. reported that the 5-year survival rates for men and women with heart failure were 25% and 38%, respectively [2] . In recent years, comprehensive treatments, such as diuretics, angiotensin converting enzyme inhibitors, b-blockers, aldosterone antagonists, and cardiac resynchronization therapy, have improved the prognosis of heart failure patients and decreased their hospitalization rates, but morbidity and mortality are still high. Cardiac remodeling is the basic mechanism of heart failure, and cardiac hypertrophy is an important part of cardiac remodeling. Myocardial hypertrophy, a compensatory mechanism in response to pressure overload, occurs slowly, often accompanied by increased protein synthesis, structural remodeling, and cardiac organelle dysfunction. Cardiomyocyte hypertrophy involves increases in cell volume, in sarcomeric and embryonic gene expression, and in collagen fiber deposition. Hypertrophy can occur with congenital heart disease, hypertension, myocardial infarction, heart failure, and other cardiovascular diseases which share common pathological processes [3, 4] . At the molecular level, the expression pattern of atrial natriuretic peptide (ANP) in myocardial cells changes, brain natriuretic peptide (BNP) production increases, the embryonic gene b-myosin heavy chain (b-MHC) activates, the expression of adult genes decreases, and myocardial protein synthesis increases. Cardiomyocytes are highly differentiated and cannot proliferate; they can only increase their volume. At the same time, the proliferation of fibroblasts, endothelial cells, and other non-myocytes can lead to other changes such as excess collagen deposition. At the organ level, there is an increase in cardiac mass, thickening of the ventricular wall, and enlargement of the heart cavity, which can manifest as diastolic dysfunction and reduced cardiac compliance [5] . Angiotensin II (Ang II) is an important initiation factor of myocardial hypertrophy [6] . Nitric oxide (NO), can cause vasodilation and reduce myocardial hypertrophy [7, 8] . At the same time, myocardial hypertrophy is often accompanied by decreased sarcoplasmic reticulum calcium pump (Ca 2+ -ATPase) activity and disorders of Ca 2+ handling [9] .
Dracocephalum heterophyllum is a genus of perennial Labiatae plants; it is also known as white flower branches, Prunella vulgaris, B. Paul (Tibetan name), and Xinjiang Uighur Mar Xan Gusi, Zupal. It is distributed in the areas of Shanxi, Inner Mongolia, Qinghai, Tibet, and Xinjiang, and is especially abundant in the village of Akto in the Autonomous Prefecture Tucker Kyrgyzstan of Xinjiang. Its whole grass contains volatile oils, flavonoids, and other constituents [10] . The aboveground part of the plant has good antibacterial and antioxidant activity, is used for myocardial protection, and treatment of coronary heart disease, and it lowers blood pressure. It is a traditional Uygur and Tibetan medicine for treating cough and stomach disease [11] , but is also used to treat jaundice, fever, liver heat, headache, nebula, oral ulcers, and bronchitis [12] . Dracocephalum heterophyllum Benth flavonoid (DHBF) has been shown to relax blood vessel constriction induced by Ang II [13] . Both endothelium-intact and endothelium-denuded vessels have been shown to be affected, but the vasodilator action was stronger with the endothelium intact. NO and prostacyclin signaling pathways were involved in the relaxation effect of DHBF on the vascular endothelium, but the vasodilatory effects of DHBF likely involved additional mechanisms.
We assumed that this was related to L-type calcium channels and the concentration of NO [14] . Given the involvement of calcium channels and NO in myocardial hypertrophy, we postulated that DHBF could also affect cardiomyocyte hypertrophy, and could be developed into a new drug to treat cardiac hypertrophy. Therefore, the objective of this study was to evaluate the inhibitory effect of DHBF on cardiomyocyte hypertrophy induced by Ang II and to observe the effects of DHBF on intracellular calcium concentration ([Ca   2+ ] i ), activity of nitric oxide synthase (NOS), and production of NO. By performing this study, we will be able to investigate the preventive effects of DHBF on myocardial hypertrophy at the cellular level.
Material and Methods

Experimental animals
Sprague Dawley neonatal rats, up to 3 days old, were provided by the experimental animal center of the Xinjiang Medical University (License number: SCXK (New) 2003-0001). The rats had been housed in a specific pathogen free (SPF) environment in Xinjiang Medical University (License number: SCXK (New) 2011-0004).
Reagents and major equipment
Valsartan was purchased from the Sino-US Shanghai Shi Guibao Co., Ltd. (Shanghai, China). Isolation and culture of primary cardiac myocytes from neonatal rats [15] The rats were subjected to an aseptic thoracotomy; the hearts were quickly removed and placed into D-Hanks solution at 4°C. One-third to one-half of the atrial portion of the hearts was removed and discarded. The remaining apical ventricular tissue was minced and left at 4°C overnight in 0.1% trypsin solution. The next day, the digestion was continued with 0.08% type II collagenase, the cells were passed through a 200-mesh nylon screen and incubated in a 100 mm Petri dish. After 90 min, the media and nonadherent cells were collected and incubated with 0.1 mmol·L -1 BrdU to inhibit non-myocyte cell proliferation. The cardiomyocytes were cultured in 25 mm culture flasks at 3×10 6 /mL, 60 mm Petri dishes at 1.5×10 6 /mL, 96-well plates at 3×10 5 /mL, and 6-well plates at 1×10 6 /mL. The cells were cultured in DMEM containing 10% calf serum for 48 hours, and then in serum-free DMEM. The incubator was set at 5% CO 2 and 37°C. A single cell synchronized beat was observed using microscopy, and the frequency was ~70-90 contractions/min. The cardiomyocytes were used for the following experiments.
Experimental grouping
Experimental grouping included 1) control; 2) Ang II; 3) Ang II+valsartan (50 μmol·L ).
Model of myocardial hypertrophy and treatments
The cultured neonatal rat cardiomyocytes were treated with Ang II (1 μmol·L 
Cell viability assay
Cardiomyocyte viability was measured by the CCK-8 method in 96-well plates. After treatments, 0.5% dimethyl sulfoxide (DMSO) was added to control cells; the other groups were washed 3 times with phosphate-buffered saline (PBS), 10 μL CCK-8 solution was added, and the cells were incubated at 37°C for 2 hours. The absorbance was then measured at a wavelength of 430 nm. Wells without cells were used for blank readings. There were 5 replicates per experiment; the experiment was repeated 3 times (n=3), and an average value was obtained. Cell survival rate (%)=(A test group -A blank )/(A control group -A blank )×100%.
RT-qPCR to detect expression of c-jun, ANP, BNP, and b-MHC mRNA as markers of hypertrophy
Myocytes were incubated and treated in 60 mm Petri dishes. After treatment, total RNA was isolated with TRIzol reagent, following manufacturer's instructions. Total RNA in diethyl pyrocarbonate (DEPC)-treated water was quantified by its A 260 and A 260 /A 280 was used to estimate its purity. RNA was reversed transcribed into cDNA. One µg cDNA was subjected to qPCR with the following cycling parameters: 95°C for 30 sec, and then 40 cycles of 95°C for 5 sec, and 62°C for 20 sec. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used for normalizing, and the relative expression level of the target genes were calculated by 2 -DD ct . The qPCR primers were designed by Shanghai Biotechnology Co., Ltd. and are shown in Table 1 .
Confocal laser scanning microscopy and detection of myocardial cell surface area
Cardiomyocytes were cultured in 6-well plates and treated with reagents for 96 hours. The cells were removed from the plate, washed 3 times with PBS, and fixed for 15 min with 4% paraformaldehyde. The cells were then permeabilized for 10 min with 0.25% Triton X-100, blocked with donkey serum at room temperature for 30 min, and then incubated at room temperature for 1 hour with antibodies against cardiac troponin T. After washing, the cells were incubated at room temperature for 1 hour (protected from light) with DyLight 594-labeled secondary antibodies, and then were stained for 3 min with 4',6-diamidino-2-phenylindole (DAPI, 1 g·mL -1 ). Images were obtained by confocal laser microscopy (LSM 710). There were 3 replicates in each of 3, independent experiments. Five different visual fields were randomly selected from each sample, and 10 cells were quantified from each field. Image-Pro 6 software was used to measure the cell surface area and the average relative surface area was calculated.
Myocytes were cultured and treated in 6-well plates. After washing 3 times with PBS, they were incubated with a calcium ion probe (Fluo-8 AM, final concentration of 5 μmol·L -1 ) in a 5% CO 2 atmosphere at 37°C for 45-60 min. After washing 3 times with PBS, the cells were analyzed by dynamic scanning using laser scanning confocal microscopy. Twenty cells were randomly selected in each group and their intracellular calcium fluorescence intensity was quantified with software.
Determining the concentration of NO in the media and activity of NOS in cell supernatants
Myocytes were incubated in 25 mm culture flasks. After treatment, both the media and cell lysates were collected. NO and NOS were measured by colorimetric methods, strictly in accordance with the kit instructions. The absorbance at 540 nm was used to measure the presence of NO 2 -after reaction with the Griess reagent; the level of NO was calculated with a standard curve. The activity of NOS was measured by the absorbance at 530 nm, following the kit instructions.
Statistical analyses
The data were analyzed using SPSS 17.0 statistical software. The data are expressed as means ± standard deviation (SD) (n=3). The t-test was used to compare 2 groups. One-way ANOVA was utilized for multi-group comparisons, with StudentNewman-Keuls testing for subsequent post-hoc comparisons between 2 groups. Differences were considered statistically significant at P<0.05.
Results
Effect of DHBF on cell survival ), but the difference was not significant (P>0.05). These results showed that the survival of cardiomyocytes, which was reduced by Ang II treatment, could be improved with DHBF co-treatment. 
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Compared with that of the valsartan and Ang II group, the myocytes that were co-treated with DHBF (50 µmol·L -1 ) showed a significant reduction in the expression of ANP and BNP (P<0.05), but no significant reduction in the expression of c-jun and b-MHC mRNA (P>0.05). The results showed that the increase in expressions of c-jun, BNP, ANP, and b-MHC mRNA in cardiomyocytes, which were induced by Ang II, could be inhibited by DHBF co-treatment, and that 50 µmol·L -1 DHBF showed a stronger effect than did valsartan.
Effect of DHBF on the surface area of cardiomyocytes
The surface area of the myocytes in each group is shown in Figure 3A and 3B. Compared with that of the control group, the surface area of the cells was significantly increased in the Ang II groups (P<0.05). Compared with that of the Ang IItreated groups, the surface area of the myocytes was significantly reduced when they were co-treated for 96 hours with different concentrations of DHBF (10, 25 , and 50 μmol·L -1 ) (P<0.05). Compared with that of the valsartan and Ang II group, the surface area of myocytes was significantly reduced with 50 µmol·L -1 DHBF (P<0.05). The results showed that the surface area of the myocytes, which was increased by Ang II, could be reduced by DHBF co-treatment, and the 50 µmol·L -1 DHBF showed a stronger effect than did valsartan. ] i induced by Ang II treatment could be inhibited by DHBF, and that 50 µmol·L -1 DHBF showed a stronger effect than did valsartan.
Effect of DHBF on the [Ca
Effect of DHBF on NO production and the activity of NOS in cardiomyocytes treated with Ang II
Compared with that of the control group, the concentration of NO in the media and the activity of NOS in the myocytes were significantly decreased when the cells were treated with Ang II (P<0.05). Compared with that of the Ang II-treated cells, the concentration of NO and the activity of NOS were increased when the cells were co-treated for 48 hours with different concentrations of DHBF (10, 25 , and 50 μmol·L -1 ), but there was no significant difference among the groups (P>0.05). However, the concentration of NO and the activity of NOS were significantly increased when the cells were co-treated for 96 hours with different concentrations of DHBF (10, 25 , and 50 μmol·L -1 ) (P<0.05). Compared with that of the valsartan and Ang II group, the concentration of NO and the activity of NOS were significantly increased with DHBF (50 μmol·L -1 ) (P<0.05). These results showed that the concentration of NO and the activity of NOS associated with hypertrophied cardiomyocytes can be increased by DHBF co-treatment, and that 50 µmol·L -1 DHBF showed a stronger effect than did valsartan ( Figure 5A , 5B). 
Discussion
The consensus in the medical profession has long been that cardiac hypertrophy, which manifests as an increase in cardiomyocyte protein and volume, is a major risk factor for cardiovascular disease in humans. Hypertrophy is often associated with changes in stromal components, decreased cardiac compliance, and decreased circulatory function; many factors are involved in the formation of myocardial hypertrophy [18] . There are many treatment methods, but the outcome is still not ideal. In view of this, it is very important to find more effective drugs and targets to inhibit cardiac hypertrophy. Myocardial hypertrophy is a complex and dynamic process that involves many factors. It has been shown that phosphatidylinositol 3-kinase/ protein kinase B, calcineurin, mitogen-activated protein kinase (MAPK), NO/cGMP, and many other signaling pathways are involved in this pathological process [18] . The renin-angiotensinaldosterone system (RAAS) and renin-catecholamine system can directly cause the development of cardiac hypertrophy.
In our study, we showed that there was a trend toward decreased expression of c-jun, ANP, BNP, and b -MHC mRNA; increased concentration of NO; and activity of NOS in cardiomyocytes after 48-hour induction by Ang II and DHBF. This may be due to the fact that the stimulation time of Ang II was insufficient to induce hypertrophy, but it may also be related to 6328 the protective effect of DHBF on cardiomyocytes. However, after 96 hours of co-treatment with DHBF and Ang II, the expression of c-jun, ANP, BNP, and b-MHC decreased significantly, and the concentration of NO and the activity of NOS increased significantly, suggesting that DHBF could inhibit cardiomyocyte hypertrophy induced by Ang II.
Ang II is the main effector molecule of RAAS. It binds to the AT1 receptor (a Gq family receptor) that is on the myocyte cell membrane, activating intracellular signaling pathways [19] . In this study, primary myocardial hypertrophy was induced by Ang II, which is commonly used as a model to evaluate cardiac hypertrophy in vitro and can exclude factors such as hemodynamic stress and other neurohumoral stimulation. By observing the mRNA expression of the proto-oncogene c-jun, cardiac hypertrophy markers, ANP, BNP, and b-MHC, as well as the surface area of the myocytes, it was confirmed that the model of cardiomyocyte hypertrophy was successful. At the same time, we observed that DHBF could significantly increase the survival of the myocytes treated with Ang II, inhibit the expression of the mRNA for c-jun, ANP, BNP, and b-MHC, and reduce the surface area of the cells, suggesting that DHBF plays an obvious preventive role in cardiomyocyte hypertrophy. and activation of PKC can lead to the early upregulation of proto-oncogenes, such as c-fos, c-myc, c-jun, and Egr-1; these genes encode proteins that act as third messengers that regulate the expression of target genes, which results in cardiac hypertrophy [20] . At the same time, Ang II could upregulate L-type-calcium channels, increasing calcium influx [21] . The results showed that the protective effect of DHBF on myocardial hypertrophy may be related to blocking the AT1 receptor and L-type calcium channels.
In our study, Ang II induced cardiomyocyte hypertrophy obviously, which was characterized by increased content of intracellular protein and increased cell volume, but the number of cells did not change, indicating no effect on cell proliferation. This can lead to increased myocardial contractility. Both the NO concentration and NOS activity decreased in the model group of myocardial hypertrophy, showing that Ang II not only can induce myocardial hypertrophy, but also can reduce the activity of NOS. These effects may be related to a1 adrenergic receptors and are mediated by the G protein that is insensitive to pertussis toxin. Adding exogenous NO was shown to prevent cardiac hypertrophy induced by Ang II, suggesting that NO not only decreases coronary vasodilation and increases coronary blood flow and myocardial contractility, but also plays an important role in preventing myocardial hypertrophy [22] . In our previous study, we found that DHBF can reduce blood pressure in renovascular hypertensive rats and can improve left ventricular systolic and diastolic function and myocardial contractility; the mechanism of DHBF may be related to decreased endothelin levels in the blood, cardiac tissue, and renal tissue, as well as increased levels of NO [8] . Our current experimental results showed that the level of NO in the DHBF group was higher than that in the model group. DHBF could inhibit cardiomyocyte hypertrophy induced by Ang II, and at the same time increase the activity of NOS in the cardiomyocytes. The resulting increased concentration of NO in the heart could elevate diastolic coronary blood flow, which could inhibit cardiac hypertrophy. These results showed that the protective effect of DHBF on cardiac hypertrophy may be related to the concentration of NO in the heart.
Increased [Ca
2+
] i is a central link in the development and progression of myocardial hypertrophy induced by external stimuli and/or intrinsic dysfunction [9] . During myocardial excitation and contraction, the calcium current is the main current of the action potential plateau, and Ca 2+ directly combines with muscle filaments to induce myocardial contraction. When the concentration of intracellular Ca 2+ drops, Ca 2+ dissociates from troponin and induces myocardial relaxation. Ca 2+ is the most important intracellular second messenger, transmitting a variety of biological signals through the cytoplasm to regulate cell growth and development, including the regulation of cardiac function [23] . Ca 2+ is also an important signaling component for cardiomyocyte hypertrophy; calmodulin (CaM) and CaMdependent protein kinase (CaMKII) are important regulatory signals. Alterations in intracellular Ca 2+ signaling are the primary stimulus for hypertrophic responses, which play a central role in cardiac hypertrophy and related gene expression. The calcineurin/nuclear factor of activated T cells (CaN/NFAT) pathway and the CaMKII/histone deacetylase (HDAC) pathway, which are Ca 2＋ -dependent, are involved [24] . At the same time, decreased activity of Ca 2+ -ATPase can lead to disorders of calcium handling, and calcium overload is an important pathophysiological mechanism leading to dysfunction of myocardial systole and diastole. Studies have shown that NO-cGMP-PKG inhibits the influx of Ca 2+ in L-type calcium channels, inhibits the activation of CaN, and weakens NFAT nuclear translocation and transcriptional activity; these all can lead to inhibition of myocardial hypertrophy. CaMKIIs may play a role in cardiac hypertrophy by activating the CREBP transcription factor family [25] . In our study, the [Ca 2＋ ] i was significantly lower in the group co-treated with DHBF than in the model group. This showed that DHBF not only could inhibit cardiomyocyte
